AstraZeneca price target lowered to 165 GBp from 172 GBp at HSBC
HSBC lowered the firm's price target on AstraZeneca to 165 GBp from 172 GBp and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperformance potential for the second half of the year, noting that the Therapeutics space offering "attractive risk weighted returns," Tools "might be the best way to play a cyclical rally," and that MedTech is "cheap."
HSBC lowered the firm's price target on AstraZeneca to 165 GBp from 172 GBp and keeps a Buy rating on the shares.
In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperformance potential for the second half of the year, noting that the Therapeutics space offering "attractive risk weighted returns," Tools "might be the best way to play a cyclical rally," and that MedTech is "cheap."